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ABSTRACT 
The Effects of Sceletium tortuosum in the Chick Anxiety-Depression Model 
(Under the direction of Kenneth J. Sufka) 
 
Sceletium tortuosum (S. tortuosum), known colloquially as Kanna, is a natural 
botanical that is thought to reduce anxiety, elevate mood, and produce euphoria.  This 
study explores S. tortuosum’s properties in the chick anxiety-depression model, a pre-
clinical drug efficacy screening model that shares many features to clinical stress-related 
disorders and has high predictive validity.  Socially-raised male Silver Laced Wyandotte 
chicks age 4-6 days were given intraperitoneal injections of either a vehicle, imipramine, 
or S. tortuosum fraction (10, 20, 30, 50, 75, or 100mg/kg) 15 minutes prior to being 
placed in a stress-inducing isolation chamber for 60 minutes and distress vocalizations 
were recorded.  Chick distress vocalizations were quantified during anxiety (first 3 
minutes) and depression-like phases (30-60 minutes, relatively).  The results show that 
vehicle-treated chicks had an initially high DVoc rate, followed by a decline and plateau 
of approximately 50%; this follows the typical pattern of anxiety, followed by behavioral 
despair that the Chick Model of Anxiety and Depression simulates.  75 and 100 mg/kg of 
S. tortuosum decreased DVoc rates during the anxiety phase, which is indicative of 
anxiolytic activity.  Imipramine groups increased DVoc rates in the depression phase, 
which is indicative of antidepressant activity; no antidepressant effect was found in S. 
tortuosum.  These findings display the potential of S. tortuosum to have stress-relieving 
properties that may alleviate anxiety-like symptoms. 
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INTRODUCTION 
 Sceletium tortuosum (S. tortuosum) is a commercially available plant originating 
in South Africa.  Leaves of the S. tortuosum genus tend to be large and succulent, with 
characteristic veins running through them.  The plant’s flowers range in color from white, 
yellow, and pink; seeds are encapsulated in the fruit portion of the plant and tend to be 
brown or black.  The genus is dispersed throughout south-western parts of South Africa, 
particularly in dry, arid environments (for review, see Gericke and Viljoen, 2008). 
The plant has been known colloquially as channa, kanna, or kougoed.  
Traditionally, the plant material has been chewed, but can also be ingested in the form of 
tea, used as snuff, or smoked.  S. tortuosum has been used to treat insomnia in adults and 
diarrhea in children; it has been thought to be a mild narcotic by indigenous people, as it 
relieves toothaches and abdominal pain.  In the United States, S. tortuosum compounds 
have been patented as pharmaceuticals for use in various psychological conditions, 
including the management of depression, anxiety, drug dependence, bulimia, and 
obsessive compulsive disorder (for review, see Gericke and Viljoen, 2008). 
There has been extensive research on the alkaloid products of S. tortuosum; 
mesembrine and mesembrenone were first isolated in 1914 by E. Zwicky (for review, see 
Gericke and Viljoen, 2008). These components have been isolated and studied for their 
effects on the central nervous system.  Harvey et al. 2011 tested purified alkaloids 
mesembrine and mesembrenone on a panel of receptors, enzymes, and drug targets to 
examine their cellular effects.  These researchers found that mesembrine was active 
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against the 5-HT transporter by blocking binding to the receptor; mesembrenone had 
some action against the 5-HT transporter and PDE4 transporter.  These findings may 
explain the clinical effects, as known 5-HT and PDE4 inhibitors reduce depression 
(Cashman et al. 2009).   
Terburg et al. 2013 tested S. tortusoum’s inhibitory properties of serotonin and 
PDE4 in human subjects in relation to anxiety.  Using fMRI’s, researchers scanned the 
brains of participants during a perceptual-load task and an emotion-matching task after 
receiving a single dose of 25mg dose of Zembrin, the standardized form of S. tortuosum, 
or a placebo.  They found that amygdala reactivity was attenuated by the test compound.  
This provides evidence that S. tortuosum may attenuate anxiety-related neurocircuitry; 
this finding also supports the anxiolytic potential of PDE4 and 5-HT reuptake inhibition 
(Terburg et al. 2013). 
Because of the historical and cultural use of S. tortuosum, a broad number of 
screening assays may be used to detect this botanical’s efficacy, side effect liability, and 
site of activity.  To do this, researchers have tested varying doses of an alkaloid extract 
fraction, varying doses of the presumed active component (mesembrine), and varying 
doses of S. tortuosum extract.  Loria et al. 2014 sought to characterize the effects of S. 
tortuosum and its extract products (alkaloid enriched extracts and mesembrine) in a 
variety of rodent-based assays that model nociception, depression, anxiety, ataxia, and 
abuse liability.   
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Conditioned place preference was used to measure the reward potential of the test 
articles (alkaloid enriched fractions, mesembrine, and S. tortuosum extracts) in order to 
gauge the abuse liability of the drug; a hot plate apparatus was used to measure analgesic 
properties of the test compound by measuring the time before a hind-paw flutter or 
escape attempt; a forced swim test was used to characterize antidepressant properties of 
the test compound by measuring behavioral despair (time spent not engaging in escape 
behavior); an elevated plus maze was used to characterize anxiolytic properties of the test 
compound by measuring time spent in the open portions of the maze; a rotarod apparatus 
was used to characterize ataxia of the test compound by measuring the time spent on the 
rotating trundle.  These assays were used to broadly characterize the effects of S. 
tortuosum (Loria et al., 2014). 
S. tortuosum test articles showed no evidence of preference or aversion in the 
conditioned place preference assay; this indicates that there is no abuse potential for the 
botanical.  S. tortuosum’s active constituent, mesembrine, showed longer latency on the 
hotplate procedure, indicating potential analgesic activity.  The alkaloid enriched fraction 
of S. tortuosum decreased behavioral despair during the forced swim test; this indicates 
that some constituents of the botanical may be useful for the treatment of mood disorders.  
S. tortuosum test compounds failed to show any anxiolytic properties in the elevated plus 
maze.  Both S. tortuosum fraction and mesembrine tended to have a shorter latency to fall 
on the rotarod test, meaning that these treatment groups could not withstand the rotating 
apparatus as long as the vehicle-treated test subjects; this may indicate some ataxia 
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caused by the botanical.  These findings indicate that S. tortuosum’s major constituent, 
mesembrine, as well as fractions of the drug have psychoactive properties that should be 
tested for further analysis of the drug (Loria et al., 2014). 
Given the potential clinical benefits of S. tortuosum, Murbach et al. 2014 sought 
to find any harm with the use of the drug during short-term use with a high dose and 
long-term use with a low dose.  These experimenters tested SPF Wistar rats that were 
orally administered high doses (25, 74, 250, and 500mg/mL) and low doses (10, 30, 45, 
and 60mg/mL) of dissolved Zembrin, the commercially available source of S. tortuosum, 
during a 14-day study and a 90-day study, respectively.  Histopathological examinations 
and toxicology reports were constructed after the final administration of the drug in both 
testing protocols; the researchers conducted examinations of hepatotoxicity to measure 
liver function, organ screenings to determine lesions, and blood chemistries to measure 
immunological functioning of the test subjects.  The experimenters found no adverse 
symptoms or mortality due to the ingestion of the drug, and provide evidence supporting 
the safety and tolerability of S. tortuosum (Murbach et al., 2014). 
Using animals as models for clinical syndromes can prove to be challenging due 
to the difficulties of translating human symptoms to animal behaviors.  Eric Nestler and 
Steven Hyman recognize the innate complications of realizing how symptoms in animal 
models explain human disorders.  Animal models are not likely to mirror the full extent 
of human disorders; instead, we must take individual symptoms in animals and attempt to 
correspond them with human symptoms.  These symptoms are not universal among 
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humans, but we rely on observation of specific behaviors to characterize depression in 
animal models.  Researchers often generate animal models of depression by exposing 
short-term stressors to normal animals; this is very different from human depression in 
that it does not consider genetic vulnerability and environmental factors that lead to 
chronic behavioral pathology.  Furthermore, researchers often administer a single dose of 
antidepressant and record a robust response; this is not in accordance with antidepressant 
response in humans (Nestler et al., 2010).  These issues of developing useful animal 
models for depression are seen repeatedly and in other neuropsychiatric conditions. 
These concerns imply that there is a lack of translational relevance between 
animal models and human conditions.  There is a need to develop and validate additional 
animal models to test novel compounds to provide further evidence of the effects of 
psychopharmacological compounds.  Because of these problems with translational 
relevance, a number of research labs have focused on developing models that better 
simulate these clinical symptoms 
The chick anxiety-depression model is a simulation of behavioral despair.  This 
assay has proven to be a well-validated screening assay for known anxiolytics and 
antidepressants, (Sufka et al., 2009; Warnick et al., 2006; Warnick et al., 2009) as well as 
novel compounds from natural products that contain anxiolytic/antidepressant properties 
(Feltenstein et al., 2003; Kochanowska et al., 2008; Lewellyn et al., 2013; Smith et al., 
2001; Sufka et al., 2001).  This model uses socially raised chicks at 4-6 days old that are 
subjected to a 1-2 hour isolation period.  Isolated chicks display an initially high rate of 
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distress vocalizations (DVocs) that decline approximately 50% within 25-30 minutes.  
This pattern replicates an anxiety phase that is followed by a depression phase.  
Anxiolytics attenuate distress vocalizations in the anxiety-like phase; antidepressants 
attenuate behavioral distress, seen by an increase in distress vocalizations during the 
depression-like phase.  This models the hypothesis that anxiety and depression are a part 
of a “temporal continuum” (Sufka et al. 2006).  Thus, this assay serves as a simultaneous 
screening tool for both anxiety and depression. 
Warnick et al. 2006 sought to distinguish the specific anxiety state in the chick 
model by screening the efficacy of anxiolytics.  Researchers explored both low-stress and 
high-stress responses by incorporating mirrors into some groups’ isolation chambers; the 
mirrors simulated a group setting (low-stress) rather than complete isolation (high-stress).  
The findings indicate that a low-stress environment led to significantly lower DVoc rates 
than those in the high-stress environment.  Furthermore, results showed that all drugs that 
are clinically effective the treatment of Panic Disorder significantly attenuated DVocs.  
This experiment adds to the validity of the chick model as an in-vivo screening assay for 
anxiety, specifically for drugs that attenuate anxiety seen in Panic Disorder (Warnick et 
al., 2006). 
In a follow-up study, Warnick et al. 2009 sought to further validate the temporal 
continuum hypothesis of anxiety and depression by utilizing the chick model of anxiety 
and depression to test the efficacy of clinically validated anxiolytics and antidepressants.  
In addition, researchers tested for biomarkers of stress; the change in cytokine levels were 
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collected and analyzed in the chick subjects.  Researchers found the DVoc pattern to be 
consistent with previous studies; anxiolytic activity was seen by chlorodiazepoxide, 
clonidine, imipramine, and maprotoline in the anxiety-like phase, and antidepressant 
activity was seen by imipramine, maprotoline, and fluoxetine in the depression-like 
phase.  Elevation in interleukin-6, a biomarker of depression, was found in response to 
social isolation during the late-depression phase of the experiment.  This study offers 
further validation of the chick model as a screening assay of clinically relevant drugs and 
as a simulator of the anxiety-depression continuum (Warnick et al., 2009). 
Sufka et al. 2009 constructed a set of experiments that utilizes the chick model to 
identify novel antidepressant compounds and identify false positives in antidepressant 
compounds that have failed in clinical trials.  In this study, all drugs had tested positive 
for antidepressant properties in rodent models and were being used test if the chick model 
was as sensitive as rodent models.  Two of the test compounds showed negative effects; 
these two compounds failed in human clinical trials, indicating that the rodent model 
gave false positive results of antidepressant properties.  Thus, the chick model avoided 
two false positives by identifying compounds that didn’t work in human clinical trials.  
This set of experiments validated the effects of anxiolytics by measuring the attenuation 
of DVocs during the anxiety phase, as well as validated clinically used antidepressants by 
evaluating the attenuation of behavioral despair. In addition, this study correctly 
identified drugs that failed in clinical trials; this assay can predict false positives that are 
not identified in rodent models. This set of experiments provides evidence for this assay’s 
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high utilization for in-vivo screening (Willner, 1991); compared to rodent models of 
behavioral distress, the chick model uses a more economical approach to screen for drug 
properties by utilizing a lower cost animal, tests at a young age, and screens for two drug 
properties in a single test (Willner, 1991).  This study provides evidence for a 
replacement assay for the traditionally used rodent model of anxiety and depression 
(Sufka et al., 2009). 
This screening assay has been validated many times for its usefulness in testing 
the efficacy of known anxiolytics and antidepressants; it has also been successful at 
screening novel compounds from natural products that possess anxiolytic/antidepressant 
properties.  Feltenstein et al. verified anxiolytic properties of Piper methysticum by 
utilizing the chick model of anxiety; researchers showed P. methysticum to attenuate 
DVocs equivalently to that of chlordiazepoxide, a clinically used anxiolytic (Feltenstein 
et al., 2003).  Other studies have since replicated the findings of novel anxiolytic and 
antidepressant properties in natural products (see Kochanowska et al., 2008; Lewellyn et 
al., 2013; Smith et al., 2001; Sufka et al., 2001). 
There is emerging evidence that S. tortuosum may alleviate stress-related disorders, as 
seen in rodent models (Loria et al. 2014); it is therefore useful to demonstrate these 
properties in other screening assays.  The chick model of anxiety and depression is a 
well-validated simulator of anxiety and depression, and has proven to provide predictive 
validity of pharmacological products.  Because no single assay can perfectly predict the 
properties of a pharmaceutical, it is worthwhile to test S. tortuosum’s on other types of 
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animal models.  Therefore, this study seeks to find the potential stress-relieving 
properties of S. tortuosum in the chick model of anxiety and depression. 
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MATERIALS AND METHODS 
Subjects and Housing 
 Male Silver Laced Wynadotte chicks were received two-days post-hatch (Gallus 
gallus, Ideal Poultry, Cameron, TX, USA) and kept in 34 x 57 x 40-cm stainless steel 
cages with approximately 12 chicks per cage.  The chicks had free access to food (Purina 
Start and Grow, St. Louis, Missouri, USA) and water via one-quart gravity feeders and 
waterers.  The room temperature was maintained at approximately 30-32°C with a 12 
hour light cycle (7am-7pm) via overhead fluorescent lighting. Daily maintenance 
included replacing paper in the chicks’ cages, and replacing food and water in the feeders 
and waterers.  
 
Apparatus 
 The testing apparatus is a six unit testing apparatus containing Plexiglas chambers 
(25cm x 25cm x 22 cm) that are equipped for collection of behavioral data.  The 
individual chambers have 25 watt light bulbs for the illumination; ventilation is achieved 
by a rotary fan within each chamber (Model FP- 108AXS1; Rodale, Great River, New 
York, USA).  Video cameras (Model PC60XP; SuperCircuit, Liberty Hill, Texas, USA) 
were placed in each testing unit that allowed for visual observation via a live stream to an 
onscreen display.  Microphones (Model 3-675-001 [modified for AC current]; Lafayette 
Instruments, Lafayette, Indiana, USA) were situated at the top of each testing unit and 
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were connected to a digital software system that continuously recorded distress 
vocalizations. 
Procedure 
 Experiment 1 tested chicks at 4-6 days post-hatch, and chicks were only tested 
one time throughout the experiment.  Imipramine-treated chicks (10mg/kg) were tested 
with chicks treated with various fractions of S. tortuosum (10mg/kg, 20mg/kg, and 
30mg/kg) and chicks treated with vehicles of the drug.  Deionized water served as the 
vehicle for imipramine; deionized water and 20% tween served as the vehicle for S. 
tortuosum. 
 Sample sizes for Imipramine and S. tortuosum groups were n=18; the vehicle groups had 
sample sizes of n=12. Intraperitoneal injections (1ml/kg) of the vehicles and drugs were 
given 15 minutes prior to testing and behavioral observations were made over a 60-
minute time period.  Distress vocalizations were continuously collected recorded 
throughout the experiment.  Once testing was complete, animals were returned to their 
home cage until the completion of the experiment and were euthanized upon completion.  
These testing procedures were approved by the University of Mississippi’s Institutional 
Animal Care and Use Committee (protocol # 16-015). 
 Experiment 2 incorporated the exact same procedure with the exception of drug 
dosages; S. tortuosum was increased to 50mg/kg, 75mg/kg, and 100mg/kg. 
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Data Analyses 
 Distress vocalizations were converted to a rate of DVocs/minute function.  
Independent t-tests revealed no statistical difference between the two vehicle groups, thus 
they were collapsed into a single control group for the remainder of data analyses.  The 
DVoc rates for the anxiety phase, and the early and late depression phases (0-3m, 31-
45m, and 46-60m) were analyzed using a one-way analysis of variance (ANOVA); post-
hoc tests were conducted using Fisher’s LSD using SPSS software.  Significance was set 
at p < 0.05. 
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RESULTS 
Experiment 1 
Figure 1 summarizes the effects of imipramine and S. tortuosum on mean DVoc rates 
during the 60-minute isolation testing period.  The vehicle-treated chicks displayed an 
initially high DVoc rate in the anxiety phase; this rate steadily decreased over the next 30 
minutes as they entered the early-depression phase (30-45 minutes), and remained 
relatively stable as the chicks entered the late-depression phase (46-60 minutes).  This 
pattern typifies the standard of stress-related DVocs in behavioral despair models of 
depression.  
Figure 2a shows that DVoc rates in the anxiety phase were not affected by either 
S. tortuosum or imipramine. A one-way ANOVA of these data failed to reveal a 
significant treatment effect, F(4,86) = 1.14, p = 0.34. No further analyses were performed 
on this data set. 
Figures 2b and c show that, relative to the vehicle-treated group, imipramine 
increased the DVoc rates during both the early (see Figure 2b) and late (see Figure 2c) 
depression phases; S. tortuosum had no effect on the early or late depression phases (see 
Figures 2b and c). A one-way ANOVA of the DVOC data in the early-depression phase 
revealed a significant treatment effect, F(4,86) = 6.06, p < 0.001. Planned comparisons 
with Fishers demonstrated that the mean DVoc rate for the imipramine group was 
significantly higher than the vehicle group, (p < 0.005) with a Cohen’s D effect size of 
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0.90. All other planned comparisons (i.e., S. tortuosum doses against vehicle group) were 
not statistically significant. 
 
Figure 1: DVoc Pattern During 60 Minute Isolation Period  
 
Figure 1 
Drug effects on the mean DVoc rate (counts per minute) as a function of isolation phase 
(anxiety 0-3 minutes; depression 30-60 minutes) with error bars that show standard error. 
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Figure 2: Mean DVocs as a Function of Treatment Group 
 
A 
	
        Treatment	
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         Treatment	
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Figure 2 
Drug effects on mean DVoc rate as a function of isolation phase. Figure A represents the 
anxiety phase; figure B, and C represent the early-depression phase and late-depression 
phase, respectively.  Asterisks denote a significant increase of DVoc relative to the 
vehicle group (p < 0.05). 
 
 
 
Finally, a one-way ANOVA of the DVoc data in the late-depression phase 
revealed a significant treatment effect, F(4,86) = 7.18, p < 0.001. Planned comparisons 
with Fishers demonstrated that the mean DVoc rate for the imipramine group was 
significantly higher than the vehicle group, (p < 0.001) with a Cohen’s D effect size of 
1.29. All other planned comparisons were not statistically significant. 
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Experiment 2 
Figure 3 summarizes the effects of imipramine and S. tortuosum on mean DVoc 
rates during the 60-minute testing period.  As in Experiment 1, the vehicle-treated chicks 
displayed an initially high DVoc rate in the anxiety phase, and decreased in the early-
depression phase, then plateaued late depression-phase.  This pattern mirrors Experiment 
1 and is typical of the standard of stress-related DVocs in behavioral despair models of 
depression. 
Figure 4a shows that groups who received high doses of S. tortuosum (75 and 
100mg/kg) displayed decreased DVoc rates during the anxiety phase.  A one-way 
ANOVA of the mean DVoc rate revealed significance for the treatment group, F(4,80) 
=3.2, p = 0.017.  Planned comparisons with Fishers demonstrated that the mean DVoc 
rate for S. tortuosum (75mg/kg and 100mg/kg) was significantly lower than the vehicle 
group, (p < 0.05) with a Cohen’s D effect size of 0.844 and 0.82, respectively.  All other 
planned comparisons (i.e., imipramine and S. tortuosum 50mg/kg against vehicle group) 
were not statistically significant.  
 Figures 4b and c show that neither imipramine or S. tortuosum-treated groups 
displayed increased DVoc rates during either half of the depression phase.  A one-way 
ANOVA of the DVoc rate failed to reveal significant treatment effect for either early or 
late-depression phases F(4,80) = 1.72, p = 0.154 and F(4,80) = 1.87, p = 0.123, 
respectively.  Planned comparisons with Fishers revealed that imipramine approached 
significance at the late-depression phase (p = 0.059) with a Cohen’s D effect size of 
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0.761.  All other planned comparisons (i.e., S. tortuosum doses against vehicle group) 
were not statistically significant.  
 
Figure 3:  DVoc Pattern During 60 Minute Isolation Period 
 
Figure 3 
Drug effects on the mean DVoc rate (counts per minute) as a function of isolation phase 
(anxiety 0-3 minutes; depression 30-60 minutes) with error bars that show standard error.   
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Figure 4:  Mean DVocs as a Function of Treatment Group 
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Figure 4 
Drug effects on mean DVoc rate as a function of isolation phase. Figure A represents the 
anxiety phase; figures B, and C represent the early-depression phase, and late-depression 
phase, respectively.  French Cross denotes a significant decrease of DVocs relative to the 
vehicle group (p < 0.05). 
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DISCUSSION 
This study sought to determine whether the antidepressant properties of S. 
tortuosum that are seen in rodent models can be generalized in another non-rodent, well 
validated screening assay.  The chick anxiety-depression model is a dual screening assay 
that induces both acute and chronic stress that triggers anxiety and depression in the test 
subject; this assay can therefore test the efficacy of anxiolytics and antidepressants.  This 
animal model has repeatedly shown high predictive validity when screening the efficacy 
of FDA-approved pharmaceuticals (Feltenstein et al., 2004; Sufka et al., 2009; Warnick 
et al., 2006, 2009) and also novel compounds that mitigate stress-related disorders 
(Feltenstein et al., 2003; Sufka et al. 2006).  This assay screened S. tortuosum for its 
ability to alleviate stress-induced behaviors that reflect anxiety and depression phases. 
The model shows a pattern of an initial high DVoc rate that is indicative of an 
anxiety phase, followed by a decline and a plateau of DVocs as the chicks enter into a 
period of behavioral despair (i.e. the depression phase).  In both experiments, the vehicle-
treated chicks’ DVoc rates showed the characteristic pattern of an initially high rate 
during the anxiety phase (first 3 minutes), followed by a gradual decline of approximately 
50% as the chicks entered into the depression phase (next 30 minutes).  This pattern is 
consistent with existing literature of the chick anxiety-depression model (Sufka et al., 
2006) and illustrates transition from a panic state into behavioral despair.   
Imipramine served as an antidepressant control and its effects in both of these 
experiments mirror the results found in previous studies (Sufka et al. 2009; Warnick et al. 
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2009).  In Experiment 1, imipramine attenuated behavioral despair; this is identified 
higher DVoc rates in both the early and late depression phase than the vehicle-treated 
chicks.  The effect of imipramine in Experiment 2 trended towards significance and had a 
very large effect size; this difference may be due to the high variance with a smaller 
sample size. 
Two S. totuosum doses (75 and 100mg/kg) reduced DVocs in the anxiety phase; 
this mirrors results of anxiolytic compounds that have previously been tested in this assay 
(Feltenstein et al., 2004; Sufka et al., 2006; Warnick et al., 2006, 2009).  S. tortuosum did 
not affect DVoc rates in either the early depression phase or late depression phase; there 
is no indication of antidepressant properties in any of the tested doses of S. tortuosum.   
The anxiolytic findings of S. tortuosum is unsurprising due to the known effects 
of this botanical on the central nervous system; lower doses show preferential binding to 
serotonin transporters, and higher doses affect GABA receptors (Harvey et al., 2011).  
GABA receptor agonists are known to possess anxiolytic effects (Feltenstein et al., 
2003), thus it is unsurprising that the two highest doses of S. tortuosum showed the 
attenuation of DVocs in the anxiety phase, which is an indication of anxiolytic activity.   
The fact that S. tortuosum fractions that were tested in this study failed to show 
anti-depressant effects is a surprising finding due to a previous study’s findings that an 
alkaloid-enriched fraction showed activity in the rat Forced Swim Test (Loria et al., 
2014).  Rodent models of depression are known to show false positives (Hyman, Nestler 
et al., 2010).  One possibility is that our current findings in the chick model represent a 
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true negative of antidepressant effects of S. tortuosum.  It may also be the case that other 
concentrations of the active constituents of S. tortuosum were not tested in this study 
show antidepressant properties; the antidepressant properties may be caused by a 
constituent of S. tortuosum that was active in the alkaloid enriched fraction that did not 
show up in the fraction that we tested in this study.  
Collectively, these findings are indicative of the following:  this botanical can 
alleviate behaviors of acute stress rather than chronic stress behavior.  This can be seen 
by the attenuation of DVocs in the anxiety phase, but the absence of attenuation of 
behavioral despair in the depression phase. 
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